STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug
STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
💡 AI analysis provides alternative perspectives on current events